ResearcherLinköping UniversityNo recent work listed

Emma Gränsmark

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5011994223. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2020: 2 papers

Papers 2

Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel. Co-author DOI 10.1186/s12885-020-07426-8 ↗
Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.01176 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Nils O. Elander · 2 shared papers, 2020 · strength 0.27
- Paper Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcita… DOI 10.1186/s12885-020-07426-8 ↗
- Paper Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer. DOI 10.3389/fonc.2020.01176 ↗
Hakon Blomstrand · 2 shared papers, 2020 · strength 0.27
- Paper Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcita… DOI 10.1186/s12885-020-07426-8 ↗
- Paper Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer. DOI 10.3389/fonc.2020.01176 ↗
Bergþór Björnsson · 1 shared paper, 2020 · strength 0.13
- Paper Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcita… DOI 10.1186/s12885-020-07426-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.